226 related articles for article (PubMed ID: 31673101)
41. Identification of cisplatin sensitizers through high-throughput combinatorial screening.
Sun Y; Jiang W; Lu W; Song M; Liu K; Chen P; Chang A; Ling J; Chiao PJ; Hu Y; Huang P
Int J Oncol; 2018 Sep; 53(3):1237-1246. PubMed ID: 29956742
[TBL] [Abstract][Full Text] [Related]
42. Process of immunogenic cell death caused by disulfiram as the anti-colorectal cancer candidate.
You SY; Rui W; Chen ST; Chen HC; Liu XW; Huang J; Chen HY
Biochem Biophys Res Commun; 2019 Jun; 513(4):891-897. PubMed ID: 31003768
[TBL] [Abstract][Full Text] [Related]
43. N-Oxide polymer-cupric ion nanogels potentiate disulfiram for cancer therapy.
Zhong Y; Sun R; Geng Y; Zhou Q; Piao Y; Xie T; Zhou R; Shen Y
Biomater Sci; 2020 Mar; 8(6):1726-1733. PubMed ID: 31995039
[TBL] [Abstract][Full Text] [Related]
44. Cannabidiol-induced activation of the metallothionein pathway impedes anticancer effects of disulfiram and its metabolite CuET.
Buchtova T; Skrott Z; Chroma K; Rehulka J; Dzubak P; Hajduch M; Lukac D; Arampatzis S; Bartek J; Mistrik M
Mol Oncol; 2022 Apr; 16(7):1541-1554. PubMed ID: 34632694
[TBL] [Abstract][Full Text] [Related]
45. Emodin enhances cisplatin-induced cytotoxicity in human bladder cancer cells through ROS elevation and MRP1 downregulation.
Li X; Wang H; Wang J; Chen Y; Yin X; Shi G; Li H; Hu Z; Liang X
BMC Cancer; 2016 Aug; 16():578. PubMed ID: 27485374
[TBL] [Abstract][Full Text] [Related]
46. Anticancer effects of disulfiram: a systematic review of in vitro, animal, and human studies.
Wang L; Yu Y; Zhou C; Wan R; Li Y
Syst Rev; 2022 Jun; 11(1):109. PubMed ID: 35655266
[TBL] [Abstract][Full Text] [Related]
47. Localized Sustained Release of Copper Enhances Antitumor Effects of Disulfiram in Head and Neck Cancer.
Wang J; Li B; Cooper RC; Huang D; Yang H
Biomacromolecules; 2024 May; 25(5):2770-2779. PubMed ID: 38687975
[TBL] [Abstract][Full Text] [Related]
48. Anti-cancer effects of disulfiram in head and neck squamous cell carcinoma via autophagic cell death.
Park YM; Go YY; Shin SH; Cho JG; Woo JS; Song JJ
PLoS One; 2018; 13(9):e0203069. PubMed ID: 30212479
[TBL] [Abstract][Full Text] [Related]
49. MLN4924 Synergistically Enhances Cisplatin-induced Cytotoxicity via JNK and Bcl-xL Pathways in Human Urothelial Carcinoma.
Ho IL; Kuo KL; Liu SH; Chang HC; Hsieh JT; Wu JT; Chiang CK; Lin WC; Tsai YC; Chou CT; Hsu CH; Pu YS; Shi CS; Huang KH
Sci Rep; 2015 Nov; 5():16948. PubMed ID: 26592553
[TBL] [Abstract][Full Text] [Related]
50. Drug-delivering-drug approach-based codelivery of paclitaxel and disulfiram for treating multidrug-resistant cancer.
Mohammad IS; Teng C; Chaurasiya B; Yin L; Wu C; He W
Int J Pharm; 2019 Feb; 557():304-313. PubMed ID: 30599232
[TBL] [Abstract][Full Text] [Related]
51. Disulfiram-loaded hollow copper sulfide nanoparticles show anti-tumor effects in preclinical models of colorectal cancer.
Jiapaer Z; Zhang L; Ma W; Liu H; Li C; Huang W; Shao S
Biochem Biophys Res Commun; 2022 Dec; 635():291-298. PubMed ID: 36327916
[TBL] [Abstract][Full Text] [Related]
52. Anti-Cancer Effects of Disulfiram in Cervical Cancer Cell Lines Are Mediated by Both Autophagy and Apoptosis.
Zhang W; Zhai Q; Li M; Huang S; Sun Z; Yan Z; Li J; Li L; Li Y
Bull Exp Biol Med; 2022 Mar; 172(5):642-648. PubMed ID: 35353287
[TBL] [Abstract][Full Text] [Related]
53. A Smart Paclitaxel-Disulfiram Nanococrystals for Efficient MDR Reversal and Enhanced Apoptosis.
Mohammad IS; He W; Yin L
Pharm Res; 2018 Feb; 35(4):77. PubMed ID: 29488114
[TBL] [Abstract][Full Text] [Related]
54. Synergy of Histone-Deacetylase Inhibitor AR-42 with Cisplatin in Bladder Cancer.
Li DR; Zhang H; Peek E; Wang S; Du L; Li G; Chin AI
J Urol; 2015 Aug; 194(2):547-55. PubMed ID: 25748177
[TBL] [Abstract][Full Text] [Related]
55. Targeting ALDH2 with disulfiram/copper reverses the resistance of cancer cells to microtubule inhibitors.
Wang NN; Wang LH; Li Y; Fu SY; Xue X; Jia LN; Yuan XZ; Wang YT; Tang X; Yang JY; Wu CF
Exp Cell Res; 2018 Jan; 362(1):72-82. PubMed ID: 29155365
[TBL] [Abstract][Full Text] [Related]
56. Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer.
Park SJ; Ye W; Xiao R; Silvin C; Padget M; Hodge JW; Van Waes C; Schmitt NC
Oral Oncol; 2019 Aug; 95():127-135. PubMed ID: 31345380
[TBL] [Abstract][Full Text] [Related]
57. Synergistic antitumor effect of triptolide and cisplatin in cisplatin resistant human bladder cancer cells.
Ho JN; Byun SS; Lee S; Oh JJ; Hong SK; Lee SE; Yeon JS
J Urol; 2015 Mar; 193(3):1016-22. PubMed ID: 25229559
[TBL] [Abstract][Full Text] [Related]
58. Disulfiram sensitizes pituitary adenoma cells to temozolomide by regulating O6-methylguanine-DNA methyltransferase expression.
Zhao Y; Xiao Z; Chen W; Yang J; Li T; Fan B
Mol Med Rep; 2015 Aug; 12(2):2313-22. PubMed ID: 25937029
[TBL] [Abstract][Full Text] [Related]
59. ATR-Chk1 signaling inhibition as a therapeutic strategy to enhance cisplatin chemosensitivity in urothelial bladder cancer.
Li CC; Yang JC; Lu MC; Lee CL; Peng CY; Hsu WY; Dai YH; Chang FR; Zhang DY; Wu WJ; Wu YC
Oncotarget; 2016 Jan; 7(2):1947-59. PubMed ID: 26657501
[TBL] [Abstract][Full Text] [Related]
60. An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer.
Seiler R; Oo HZ; Tortora D; Clausen TM; Wang CK; Kumar G; Pereira MA; Ørum-Madsen MS; Agerbæk MØ; Gustavsson T; Nordmaj MA; Rich JR; Lallous N; Fazli L; Lee SS; Douglas J; Todenhöfer T; Esfandnia S; Battsogt D; Babcook JS; Al-Nakouzi N; Crabb SJ; Moskalev I; Kiss B; Davicioni E; Thalmann GN; Rennie PS; Black PC; Salanti A; Daugaard M
Eur Urol; 2017 Jul; 72(1):142-150. PubMed ID: 28408175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
